Published in Neurology on March 01, 1997
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health (1998) 9.58
NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest (2003) 3.50
Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol (1998) 2.85
Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ (2003) 2.74
Role of toll-like receptor signalling in Abeta uptake and clearance. Brain (2006) 2.70
Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med (2012) 2.36
The microglial "activation" continuum: from innate to adaptive responses. J Neuroinflammation (2005) 2.23
Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener (2009) 2.23
Toll-like receptors in neurodegeneration. Brain Res Rev (2008) 2.15
Reimagining Alzheimer's disease--an age-based hypothesis. J Neurosci (2010) 2.12
Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol (1999) 2.10
The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation (2008) 2.03
NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology (2007) 1.88
Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc Natl Acad Sci U S A (1998) 1.77
Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14-prostaglandin J2. Proc Natl Acad Sci U S A (1999) 1.74
Neuroinflammatory processes in Alzheimer's disease. J Neural Transm (Vienna) (2010) 1.73
Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat (2009) 1.69
Toll-like receptor 4 in CNS pathologies. J Neurochem (2010) 1.68
Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. J Neuroinflammation (2011) 1.68
Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation (2008) 1.67
Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol (1999) 1.65
Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation (2005) 1.64
Alzheimer disease. Dis Mon (2010) 1.64
Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am J Pathol (1999) 1.60
Oleuropein in olive and its pharmacological effects. Sci Pharm (2010) 1.53
Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism. Proc Natl Acad Sci U S A (1998) 1.48
Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Am J Pathol (2004) 1.47
No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology (2008) 1.45
Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain (2008) 1.42
Alzheimer's disease - a neurospirochetosis. Analysis of the evidence following Koch's and Hill's criteria. J Neuroinflammation (2011) 1.41
Alzheimer's disease and mild cognitive impairment. Neurol Clin (2007) 1.39
The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann Neurol (2008) 1.38
Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease. Ann Neurol (2012) 1.37
Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol Aging (2006) 1.37
Treatment strategies targeting amyloid β-protein. Cold Spring Harb Perspect Med (2012) 1.37
Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am J Pathol (2001) 1.34
Dementia and its implications for public health. Prev Chronic Dis (2006) 1.30
Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J Neuroinflammation (2008) 1.30
Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut (2001) 1.29
Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1beta and inducible nitric oxide synthase in the rat model of Alzheimer's disease. BMC Neurosci (2006) 1.28
NADPH oxidase as a therapeutic target in Alzheimer's disease. BMC Neurosci (2008) 1.27
Toll-like receptors in Alzheimer's disease. Curr Top Microbiol Immunol (2009) 1.27
The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. J Neuroinflammation (2006) 1.25
Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol (2008) 1.23
NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J Clin Invest (2009) 1.23
Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimers Res Ther (2010) 1.20
Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. Proc Natl Acad Sci U S A (1998) 1.17
Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. CNS Neurol Disord Drug Targets (2011) 1.16
Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. J Neuroinflammation (2005) 1.16
Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models. J Clin Invest (2014) 1.15
Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid. Aging (Albany NY) (2009) 1.13
PGH2-derived levuglandin adducts increase the neurotoxicity of amyloid beta1-42. J Neurochem (2006) 1.12
Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis. J Neuroinflammation (2004) 1.10
Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders. Am J Neurodegener Dis (2013) 1.08
Drug development for Alzheimer's disease: where are we now and where are we headed? Am J Geriatr Pharmacother (2009) 1.07
Fatty acid oxidation in the pathogenesis of Alzheimer's disease. Am J Pathol (2005) 1.04
Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study. BMC Geriatr (2005) 1.03
Neuroinflammation in Alzheimer's disease; A source of heterogeneity and target for personalized therapy. Neuroscience (2014) 1.01
PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. Neurobiol Aging (2008) 1.00
Prostaglandins are necessary and sufficient to induce contextual fear learning impairments after interleukin-1 beta injections into the dorsal hippocampus. Neuroscience (2007) 1.00
Tooth loss, apolipoprotein E, and decline in delayed word recall. J Dent Res (2010) 0.99
Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity. Anal Biochem (2007) 0.98
Causes of Alzheimer's disease. CMAJ (2000) 0.98
Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? Front Aging Neurosci (2010) 0.98
Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease. Neurobiol Aging (2010) 0.97
Mitochondrial dynamics in Alzheimer's disease: opportunities for future treatment strategies. Drugs Aging (2010) 0.95
Vitamin E (alpha-tocopherol) attenuates cyclo-oxygenase 2 transcription and synthesis in immortalized murine BV-2 microglia. Biochem J (2003) 0.93
Aspirin and other anti-inflammatory drugs. Thorax (2000) 0.93
Catalytic antioxidants and neurodegeneration. Antioxid Redox Signal (2009) 0.93
Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target. J Clin Immunol (2014) 0.93
Cardioprotective and neuroprotective roles of oleuropein in olive. Saudi Pharm J (2010) 0.92
Cyclopentenone eicosanoids as mediators of neurodegeneration: a pathogenic mechanism of oxidative stress-mediated and cyclooxygenase-mediated neurotoxicity. Brain Pathol (2005) 0.92
Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology. J Neuroinflammation (2012) 0.91
The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer's disease. Immunology (2014) 0.91
Characterization of scavengers of gamma-ketoaldehydes that do not inhibit prostaglandin biosynthesis. Chem Res Toxicol (2010) 0.91
Nonsteroidal anti-inflammatory drugs, aspirin, and cognitive function in the Baltimore longitudinal study of aging. J Am Geriatr Soc (2010) 0.90
The prediction and prevention of Alzheimer's disease--towards a research agenda. J Psychiatry Neurosci (1999) 0.90
What are all the things that aspirin does? BMJ (2003) 0.90
Molecular modeling study on chemically diverse series of cyclooxygenase-2 selective inhibitors: generation of predictive pharmacophore model using catalyst. J Mol Model (2008) 0.89
Neuroprotective effects of meloxicam and selegiline in scopolamine-induced cognitive impairment and oxidative stress. Int J Alzheimers Dis (2012) 0.89
Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies. Int Psychogeriatr (2008) 0.89
Effects of S-2474, a novel nonsteroidal anti-inflammatory drug, on amyloid beta protein-induced neuronal cell death. Br J Pharmacol (2001) 0.89
Chemical Biology, Molecular Mechanism and Clinical Perspective of γ-Secretase Modulators in Alzheimer's Disease. Curr Neuropharmacol (2011) 0.89
Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases. J Neurochem (2010) 0.89
Intermittent fasting attenuates lipopolysaccharide-induced neuroinflammation and memory impairment. J Neuroinflammation (2014) 0.89
Nitric oxide in neurodegeneration: potential benefits of non-steroidal anti-inflammatories. Neurosci Bull (2011) 0.87
PPARgamma, neuroinflammation, and disease. J Neuroinflammation (2004) 0.86
Alzheimer's disease. Dialogues Clin Neurosci (2000) 0.86
Medications and diet: protective factors for AD? Alzheimer Dis Assoc Disord (2006) 0.85
Characterisation of amyloid-induced inflammatory responses in the rat retina. Exp Brain Res (2011) 0.85
Targeting innate immunity for neurodegenerative disorders of the central nervous system. J Neurochem (2016) 0.85
Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. Int J Exp Pathol (2005) 0.85
Therapeutic implications of the prostaglandin pathway in Alzheimer's disease. Biochem Pharmacol (2014) 0.85
Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging. J Neuroinflammation (2014) 0.85
Microglial Malfunction: The Third Rail in the Development of Alzheimer's Disease. Trends Neurosci (2015) 0.85
NO-flurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade. J Neurochem (2009) 0.84
Microsomal prostaglandin E synthase-2: cellular distribution and expression in Alzheimer's disease. Exp Neurol (2009) 0.84
Does low-dose acetylsalicylic acid prevent cognitive decline in women with high cardiovascular risk? A 5-year follow-up of a non-demented population-based cohort of Swedish elderly women. BMJ Open (2012) 0.84
Frontiers in Alzheimer's disease therapeutics. Ther Adv Chronic Dis (2011) 0.84
Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health (1998) 9.58
Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab (2001) 7.53
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA (1992) 6.40
One-year age changes in MRI brain volumes in older adults. Cereb Cortex (2000) 5.16
Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA (2000) 3.99
Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology (1988) 3.40
Age and gender comparisons of muscle strength in 654 women and men aged 20-93 yr. J Appl Physiol (1985) (1997) 3.05
A validation study of the Dementia Questionnaire. Arch Neurol (1994) 2.89
Development of dementing illnesses in an 80-year-old volunteer cohort. Ann Neurol (1989) 2.49
Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol (1997) 2.43
Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology (2001) 2.38
Muscle quality. I. Age-associated differences between arm and leg muscle groups. J Appl Physiol (1985) (1999) 2.31
A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology (1997) 2.30
Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol (2001) 2.07
Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology (1995) 1.92
Free testosterone and risk for Alzheimer disease in older men. Neurology (2004) 1.88
Capsid size and deoxyribonucleic acid length: the petite variant of bacteriophage T4. J Virol (1970) 1.84
Neuropsychological characteristics of mild cognitive impairment subgroups. J Neurol Neurosurg Psychiatry (2005) 1.83
Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Ann Neurol (1982) 1.77
Reliability of the Blessed Telephone Information-Memory-Concentration Test. J Geriatr Psychiatry Neurol (1995) 1.72
Transient global amnesia: clinical characteristics and prognosis. Neurology (1987) 1.72
Determinants of vascular dementia in the Cardiovascular Health Cognition Study. Neurology (2005) 1.70
Subcortical aphasia and neglect in acute stroke: the role of cortical hypoperfusion. Brain (2002) 1.70
Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate (1990) 1.69
Increased carotid artery intimal-medial thickness in asymptomatic older subjects with exercise-induced myocardial ischemia. Circulation (1998) 1.65
Gender differences in a longitudinal study of age-associated hearing loss. J Acoust Soc Am (1995) 1.63
Leisure-time physical activities and their relationship to cardiorespiratory fitness in healthy men and women 18-95 years old. Med Sci Sports Exerc (2000) 1.52
Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab (2000) 1.49
Learning and retention in preclinical and early Alzheimer's disease. Psychol Aging (1997) 1.48
Risk factors related to age-associated hearing loss in the speech frequencies. J Am Acad Audiol (1996) 1.47
Age-specific norms for the Mini-Mental State Exam. Neurology (1988) 1.42
Muscle quality. II. Effects Of strength training in 65- to 75-yr-old men and women. J Appl Physiol (1985) (1999) 1.40
Rapid decline in FEV1. A new risk factor for coronary heart disease mortality. Am J Respir Crit Care Med (1995) 1.37
Effects of strength training and detraining on muscle quality: age and gender comparisons. J Gerontol A Biol Sci Med Sci (2000) 1.33
Work-related disability: results from the American migraine study. Cephalalgia (1996) 1.32
Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate (1990) 1.29
Female preclinical presenilin-1 mutation carriers unaware of their genetic status have higher levels of depression than their non-mutation carrying kin. J Neurol Neurosurg Psychiatry (2004) 1.27
Diagnostic validity of the dementia questionnaire for Alzheimer disease. Arch Neurol (1998) 1.22
Slowly progressive aphasia: three cases with language, memory, CT and PET data. J Neurol Neurosurg Psychiatry (1990) 1.22
Effects of human aging on patterns of local cerebral glucose utilization determined by the [18F]fluorodeoxyglucose method. J Cereb Blood Flow Metab (1982) 1.21
A new xeroderma pigmentosum group C poly(AT) insertion/deletion polymorphism. Carcinogenesis (2000) 1.21
Age and gender responses to strength training and detraining. Med Sci Sports Exerc (2000) 1.19
DAF as instrumental treatment for dysarthria in progressive supranuclear palsy: a case report. J Speech Hear Disord (1980) 1.17
Classification of vascular dementia in the Cardiovascular Health Study Cognition Study. Neurology (2005) 1.17
Serum protein signatures detect early radiographic osteoarthritis. Osteoarthritis Cartilage (2008) 1.15
Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res (1992) 1.15
Neuropathologic features associated with Alzheimer disease diagnosis: age matters. Neurology (2011) 1.15
Prostatic growth rate determined from MRI data: age-related longitudinal changes. J Androl (1999) 1.14
Adult life span changes in immediate visual memory and verbal intelligence. Psychol Aging (1995) 1.13
Estrogen replacement therapy and longitudinal decline in visual memory. A possible protective effect? Neurology (1997) 1.13
Neuropsychological function in nondemented carriers of presenilin-1 mutations. Neurology (2005) 1.13
Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain. Neurobiol Aging (2006) 1.11
Sources of variability in prevalence rates of Alzheimer's disease. Int J Epidemiol (1995) 1.09
Predicting rate of cognitive decline in probable Alzheimer's disease. Brain Cogn (1996) 1.09
Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging. Urology (1991) 1.08
Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology (1995) 1.08
Hemodynamic changes during aging associated with cerebral blood flow and impaired cognitive function. Neurobiol Aging (2000) 1.07
Effects of stroke on local cerebral metabolism and perfusion: mapping by emission computed tomography of 18FDG and 13NH3. Ann Neurol (1980) 1.05
High-volume, heavy-resistance strength training and muscle damage in young and older women. J Appl Physiol (1985) (2000) 1.03
Muscle size responses to strength training in young and older men and women. J Am Geriatr Soc (2001) 1.02
Cerebral metabolic relationships for selected brain regions in Alzheimer's, Huntington's, and Parkinson's diseases. J Cereb Blood Flow Metab (1984) 1.01
Relationship between muscle strength and the time taken to complete a standardized walk-turn-walk test. J Gerontol A Biol Sci Med Sci (2001) 1.01
Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. Urology (1996) 1.01
Skeletal muscle satellite cell populations in healthy young and older men and women. Anat Rec (2000) 1.01
Language production in Parkinson's disease: acoustic and linguistic considerations. Brain Lang (1988) 1.00
Skeletal muscle satellite cell characteristics in young and older men and women after heavy resistance strength training. J Gerontol A Biol Sci Med Sci (2001) 1.00
Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method. Ann Neurol (1984) 1.00
CNTF genotype is associated with muscular strength and quality in humans across the adult age span. J Appl Physiol (1985) (2001) 0.99
The relationship of motor unit size, firing rate and force. Clin Neurophysiol (1999) 0.99
The physical functioning inventory: a procedure for assessing physical function in adults. J Aging Health (2001) 0.97
Cerebral metabolic relationships for selected brain regions in healthy adults. J Cereb Blood Flow Metab (1984) 0.97
Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging. Neurobiol Aging (2005) 0.97
Longitudinal changes in smell identification. J Gerontol A Biol Sci Med Sci (1996) 0.95
Reversible dementia with idiopathic hypereosinophilic syndrome. Neurology (1989) 0.94
Carotid arterial stiffness as a surrogate for aortic stiffness: relationship between carotid artery pressure-strain elastic modulus and aortic pulse wave velocity. Ultrasound Med Biol (1999) 0.94
Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate (1995) 0.94
The relationship between longitudinal declines in dehydroepiandrosterone sulfate concentrations and cognitive performance in older men. Arch Intern Med (2000) 0.93
Comparison of metabolic rates, language, and memory in subcortical aphasias. Brain Lang (1983) 0.92
Electromyographic patterns suggest changes in motor unit physiology associated with early osteoarthritis of the knee. Osteoarthritis Cartilage (2007) 0.91
IGF2 genotype and obesity in men and women across the adult age span. Int J Obes Relat Metab Disord (2002) 0.91
Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease. Ann Neurol (1984) 0.91
Influence of age and postmenopausal estrogen replacement therapy on carotid arterial stiffness in women. Cardiovasc Res (1999) 0.90
The Direct Assessment of Functional Abilities (DAFA): a comparison to an indirect measure of instrumental activities of daily living. Gerontologist (1998) 0.90
The effect of normal aging on patterns of local cerebral glucose utilization. Ann Neurol (1984) 0.90
Local cerebral glucose utilization in symptomatic and presymptomatic Huntington's disease. Res Publ Assoc Res Nerv Ment Dis (1985) 0.90
Clinical and acoustical variability in hypokinetic dysarthria. J Commun Disord (1986) 0.89
Sex hormone binding globulin levels across the adult lifespan in women--the role of body mass index and fasting insulin. J Endocrinol Invest (2008) 0.88
Cognitive and brain imaging measures of Alzheimer's disease. Neurobiol Aging (1988) 0.87
FDG positron emission computed tomography in a study of aphasia. Ann Neurol (1981) 0.87
Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology (1997) 0.86
Impaired ranking of semantic attributes in dementia. Brain Lang (1985) 0.86
Correlations of glucose metabolism and structural damage to language function in aphasia. Brain Lang (1984) 0.86
Ultrastructural muscle damage in young vs. older men after high-volume, heavy-resistance strength training. J Appl Physiol (1985) (1999) 0.85
Prostate-specific antigen testing of older men. J Natl Cancer Inst (1999) 0.85
Next steps in describing aging and disease in longitudinal studies. J Gerontol (1990) 0.85
Longitudinal influence of age, menopause, hormone replacement therapy, and other medications on parotid flow rates in healthy women. J Gerontol A Biol Sci Med Sci (2000) 0.83
Disconnection and cerebral metabolism. The case of conduction aphasia. Arch Neurol (1988) 0.83
Cerebral glucose metabolism as a function of age in man: influence of the rate constants in the fluorodeoxyglucose method. J Cereb Blood Flow Metab (1983) 0.83